IPP Bureau

Roche inaugurates new research home for the Institute of Human Biology
Roche inaugurates new research home for the Institute of Human Biology

By IPP Bureau - March 24, 2026

The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients

Japan okays new long-acting eye drug
Japan okays new long-acting eye drug

By IPP Bureau - March 24, 2026

It promises fewer injections for vision loss patients

Bayer wins world-first nod in Japan for low-dose MRI contrast agent
Bayer wins world-first nod in Japan for low-dose MRI contrast agent

By IPP Bureau - March 24, 2026

Call it a major breakthrough for diagnostic imaging

Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results
Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results

By IPP Bureau - March 24, 2026

The company plans to submit the vaccine for regulatory review

Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug
Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug

By IPP Bureau - March 24, 2026

The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials

Somerset smashes fund target, raises $288M to power India’s healthcare transformation
Somerset smashes fund target, raises $288M to power India’s healthcare transformation

By IPP Bureau - March 24, 2026

Zydus launches affordable Semaglutide in India after patent expiry
Zydus launches affordable Semaglutide in India after patent expiry

By IPP Bureau - March 23, 2026

Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders

Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy
Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy

By IPP Bureau - March 23, 2026

The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety

Godavari Biorefineries secures Japanese patent for antiviral compounds
Godavari Biorefineries secures Japanese patent for antiviral compounds

By IPP Bureau - March 23, 2026

The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways

Government constitutes National Dental Commission to transform dental education
Government constitutes National Dental Commission to transform dental education

By IPP Bureau - March 23, 2026

The government has appointed Dr. Sanjay Tewari as Chairperson, National Dental Commission and Dr. Mousumi Goswami, Part-Time Member, National Dental Commission

Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026
Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026

By IPP Bureau - March 23, 2026

Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses

Avid Organics launches first commercial-scale bio-based glycolic acid at in-cosmetics Global
Avid Organics launches first commercial-scale bio-based glycolic acid at in-cosmetics Global

By IPP Bureau - March 23, 2026

India’s largest glycolic acid manufacturer will unveil AviGa Bio HP70 on April 14, 2026

LGM Pharma commits $15M to US facilities in major CDMO expansion
LGM Pharma commits $15M to US facilities in major CDMO expansion

By IPP Bureau - March 23, 2026

This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing

TRIANA Biomedicines doses first patient in groundbreaking ALK+ lung cancer trial
TRIANA Biomedicines doses first patient in groundbreaking ALK+ lung cancer trial

By IPP Bureau - March 23, 2026

The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611

$7 million grant to UW Institute for protein design to fuel next-gen enzyme breakthroughs
$7 million grant to UW Institute for protein design to fuel next-gen enzyme breakthroughs

By IPP Bureau - March 23, 2026

The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington

Latest Stories

Interviews

Packaging